Auto-immune

Delve into the world of Auto-immune in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on Auto-immune to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

European Commission Approves AbbVie's RINVOQ (Upadacitinib) for Juvenile Idiopathic Arthritis – Ninth EU Indication for the JAK Inhibitor
CompanyDrug

European Commission Approves AbbVie’s RINVOQ (Upadacitinib) for Juvenile Idiopathic Arthritis – Ninth EU Indication for the JAK Inhibitor

AbbVie Inc. (NYSE: ABBV) announced that the European Commission (EC) has approved RINVOQ (upadacitinib) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients aged 2 years and…

Novo Nordisk Says 1.5 Million Patients Are Now on the Oral Wegovy Pill – Capacity to Expand 10‑Fold by 2030 as Sales Growth Outpaces Eli Lilly's Foundayo

Novo Nordisk Says 1.5 Million Patients Are Now on the Oral Wegovy Pill – Capacity to Expand 10‑Fold by 2030 as Sales Growth Outpaces Eli Lilly’s Foundayo

Asieris Doses First Patient in Phase I/II Trial of APL‑2501 – Anti‑CLDN6/9 ADC Advances Toward Ovarian, Lung, Endometrial and Gastric Cancers

Asieris Doses First Patient in Phase I/II Trial of APL‑2501 – Anti‑CLDN6/9 ADC Advances Toward Ovarian, Lung, Endometrial and Gastric Cancers

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

Lynk Pharmaceuticals Secures Series C2 Financing to Advance pipeline

CompanyDrug

Jiangsu Hengrui Pharmaceuticals Wins NMPA Approval for Two Novel Drug Candidates

CompanyDrug

Pfizer’s Litfulo Earns EU Approval as First Treatment for Severe Alopecia Areata in Teens

CompanyDeals

Menarini Group Secures Exclusive License for Astellas’ Smyraf in Taiwan

CompanyDrug

FDA Accepts Takeda’s Filing for Subcutaneous Entyvio as Maintenance Therapy for Crohn’s Disease

CompanyDrug

AbbVie’s Skyrizi Outperforms Janssen’s Stelara in Phase III Crohn’s Disease Trial

CompanyDeals

JW Therapeutics and 2seventy Bio Expand Partnership for Cell Therapy Development

CompanyDeals

Sandoz Inks Deal with Samsung Bioepis for Ustekinumab Biosimilar SB17

Show More